635 results on '"Bertotti, Andrea"'
Search Results
2. Author Correction: Pathway level subtyping identifies a slow-cycling biological phenotype associated with poor clinical outcomes in colorectal cancer
3. Multi-label transcriptional classification of colorectal cancer reflects tumor cell population heterogeneity
4. Preclinical efficacy of a HER2 synNotch/CEA-CAR combinatorial immunotherapy against colorectal cancer with HER2 amplification
5. The biomedicalization of pregnancy prevention, neoliberal feminism, and college women's experiences of the contraceptive paradox
6. Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts.
7. A modified fluctuation-test framework characterizes the population dynamics and mutation rate of colorectal cancer persister cells
8. Colorectal cancer patient-derived organoids and cell lines harboring ATRX and/or DAXX mutations lack Alternative Lengthening of Telomeres (ALT)
9. How Ignoring the Fundamental Causes of Maternal Morbidity/Mortality Impedes Progress Toward a Reproductive Justice Model of Contraceptive Counseling
10. Supplementary Figure 1 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
11. Supplementary Table 1 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
12. Supplementary Table 8 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
13. Supplementary Table 5 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
14. Supplementary Figure 5 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
15. Supplementary Table 2 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
16. Supplementary Table 9 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
17. Supplementary Table 7 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
18. Supplementary Figure 6 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
19. Supplementary Table 3 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
20. Supplementary Methods 1 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
21. Supplementary Figure 3 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
22. Supplementary Table 6 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
23. Supplementary Figure 2 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
24. Supplementary Table 4 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
25. Supplementary Figure 4 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
26. Data from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
27. The EurOPDX Data Portal: an open platform for patient-derived cancer xenograft data sharing and visualization
28. Effective drug combinations in breast, colon and pancreatic cancer cells
29. Chromatin Velocity reveals epigenetic dynamics by single-cell profiling of heterochromatin and euchromatin
30. PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models
31. Heterogeneity and evolution of DNA mutation rates in microsatellite stable colorectal cancer
32. Pathway level subtyping identifies a slow-cycling and transcriptionally lethargic biological phenotype associated with poor clinical outcomes in colon cancer independent of genetics
33. DNA Microarray Classification: Evolutionary Optimization of Neural Network Hyper-parameters
34. Understanding Cancer Phenomenon at Gene Expression Level by using a Shallow Neural Network Chain
35. Efficacy as safety: Dominant cultural assumptions and the assessment of contraceptive risk
36. Quantifying single-cell ERK dynamics in colorectal cancer organoids reveals EGFR as an amplifier of oncogenic MAPK pathway signalling
37. Patient-derived tumor models: a more suitable tool for pre-clinical studies in colorectal cancer
38. PhyliCS: a Python library to explore scCNA data and quantify spatial tumor heterogeneity
39. Constructing contentious and noncontentious facts : How gynecology textbooks create certainty around pharma-contraceptive safety
40. Immunogenomics of Colorectal Tumors: Facts and Hypotheses on an Evolving Saga
41. Phosphoproteomics of patient-derived xenographs identifies targets and markers associated with sensitivity and resistance to EGFR blockade in colorectal cancer
42. DNA Microarray Classification: Evolutionary Optimization of Neural Network Hyper-parameters
43. Understanding Cancer Phenomenon at Gene Expression Level by using a Shallow Neural Network Chain
44. Rituximab Treatment Prevents Lymphoma Onset in Gastric Cancer Patient-Derived Xenografts
45. Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens
46. CONNECTOR, fitting and clustering of longitudinal data to reveal a new risk stratification system
47. Abstract 4327: MSI cancer associated DNA (TA)n-dinucleotide repeat expansions and implications for Werner synthetic lethality
48. Supplementary Figure S2 from Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
49. Supplementary Figure 3 from EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer
50. Supplementary Table 1 from A Molecularly Annotated Platform of Patient-Derived Xenografts (“Xenopatients”) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.